A senior research analyst at a broker-dealer receives an unsolicited phone call from a close relative who works as a clinical study coordinator at a publicly traded biopharmaceutical company. The relative reveals unreleased Phase III trial results showing that a flagship drug candidate failed to meet its primary efficacy endpoints. Knowing this information is confidential, the analyst does not trade for their personal account, but immediately communicates the negative finding to a favored institutional client, who then sells short 50,000 shares of the biopharmaceutical company prior to the public announcement. Under federal securities laws governing insider trading, which of the following statements correctly evaluates the legal liability of the analyst and the institutional client?
- Both the analyst and the institutional client may be held liable under insider trading regulations, as the information was material and nonpublic, a breach of duty occurred, and a trade was executed based on the tip.Cevap
- BOnly the institutional client can be held liable because liability under insider trading laws applies exclusively to the individual or entity that actually executes transactions and realizes financial gain.
- CNeither the analyst nor the institutional client can be held liable because the institutional client is not an insider of the biopharmaceutical company and owes no fiduciary duty to its shareholders.
- DOnly the analyst can be held liable because registered representatives are subject to FINRA jurisdiction, whereas outside institutional investors are exempt from insider trading provisions.